Pharmacological approaches to targeting muscarinic acetylcholine receptors

Recent Patents on CNS Drug Discovery

Volumn 9, Issue 2, 2014, Pages 85-100

  Matera, Carlo ^a   Tata, Ada M ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bitopic ligands; Multiple sclerosis; Muscarinic receptors; Neurological diseases; Nociception; Tumors

Indexed keywords

ACETYLCHOLINE; DARIFENACIN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; US5096890; US6106864;

ANALGESIA; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG TARGETING; HUMAN; LIGAND BINDING; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 84919771055     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889809666141120131238     Document Type: Article

References (152)

1. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The biological role of non neuronal acetylcholine in plants and humans. Jap J Pharmacol 2001; 85: 2-10.
2. Oettling G, Götz U, Drews U. Characterization of the Ca2 + influx into embryonic cells after stimulation of the embryonic muscarinic receptors. J Dev Physiol 1992; 17: 147-55.
3. Buzanikov GA, Shumukler YB, Lauder JM. From oocytes to neuron: do neurotransmitters function in the same way throughout development. Cell Mol Neurobiol 1996; 16: 533-59.
4. Grando SA, Pittelkow MR, Schellreunter KU. Adrenergic and cholinergic control in the biology of epidermis: physiological and clinical Significance. J Invest Dermatol 2006; 126: 1948-65.
5. Kawashima K, Fuji T. Expression of non neuronal acetylcholine in lymphocytes and its contributionof immune function. Front Biosci 2004; 9 (suppl): 2063-85.
6. Proskocil BJ, Harmanjatinder SS, Yibing J, Savchenk V, Blakely RD, Lindstrom J, et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinol 2004; 145: 2498-506.
7. Whittacher VP. Identification of acetylcholine and related esters of biological origin. In Eichler O, Farah A, Koelle GB Eds. Handbuch der Experimentellen Pharmakologie. B, Heidelberg: New York Springer 1963: 1-39.
8. Wessler I, Kilbinger H, Bittinger F, Unger R, Kirkpatrick CJ. The non-neuronal cholinergic system in humans: Expression, function and pathophysiology. Life Sci 2003; 72: 2055-61.
9. Ma W, Li BS, Zhang L, Pant H. Signalling cascades implicated in muscarinic regulation of proliferation of neural stem and progenitor cells. Drug News Perspect 2004; 17: 258-66.
10. Zhou C, Wen ZX, Shi DM, Xie ZP. Muscarinic acetylcholine receptors involved in the regulation of neural stem cell proliferation and differentiation in vitro. Cell Biol Inter 2004; 28: 63-67.
11. Augusti-Tocco G, Biagioni S, Tata AM. Acetylcholine and regulation of gene expression in developing systems. J Mol Neurosci 2006; 30: 45-47.
12. Magnaghi V, Procacci P, Tata AM. Novel pharmacological approaches to Schwann cells as neuroprotective agents for peripheral nerve regeneration. Int Rev Neurobiol 2009; 87: 295-315.
13. Loreti S, Ricordy R, De Stefano ME, Augusti-Tocco G, Tata AM. Acetylcholine inhibits cell cycle progression in rat Schwann cells by activation of M2 receptor subtype. Neuron Glia Biol 2007; 3: 269-79.
14. De Angelis F, Bernardo A, Magnaghi V, Minghetti L, Tata AM. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation and differentiation. Dev Neurobiol 2012; 72: 713-28.
15. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron 2009; 64: 28-32.
16. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48.
17. Reale M, De Angelis F, Di Nicola M, Capello E, di Ioia M, De Luca G, et al. Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci 2012; 13: 12656-664.
18. De Simone R, Ajmone-Cat Ma, Carnevale D, Minghetti L. Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J Neuroinflamm 2005; 25: 1-10.
19. Levey AI. Immunological localization of m1-m5 muscarinic receptor subtypes in peripheral tissues and brain. Life Sci 1993; 52: 441-48.
20. Ragheb F, Molina-Holgado E, Cui QL, Khorchid A, Liu HN, Larocca JN, et al. Pharmacological and functional characterization of muscarinic receptor subtypes in developing oligodendrocytes. J Neurochem 2001; 77: 1396-406.
21. Loreti S, Vilarò MT, Visentin S, Rees H, Levey AI, Tata AM. Rat Schwann cells express M1-M4 muscarinic receptor subtypes. J Neurosci Res 2006; 84: 97-105.
22. Caufield MP, Birdsall NJM. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90.
23. Levine RR, Birdsall NJM. Subtypes of muscarinic receptors. Proceedings of the 4th international symposium on subtypes of muscarinic receptors. Trends Pharmacol Sci 1989; 10(suppl): S1-s119.
24. Hulme EC, Birsall NJM, Buckley NJ. Muscarinic receptor subtypes. Ann Rev Pharmacol Toxicol 1990; 30: 633-73.
25. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distint primary structures, ligand binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987; 6: 3923-29.
26. Caufield MP. Muscarinic receptors: characterization, coupling and function. Pharmacol Ther 1993; 58: 319-79.
27. Taylor P, Brown JH. Acetylcholine. In: Siegel GJ, Agranoff BW, Albers RW, Molinoff PB. Basic Neurochemistry. Raven Press 1994.
28. Tence M, Cordier J, Premont J, Glowinski J. Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture. J Pharmacol Exp Ther 1994; 269: 646-53.
29. Conklin BR, Brann MR, Buckley MJM, Bonner IT, Axelrod J. Stimulation of arachidonic acid release and inhibitionof mitogenesis by cloned genes for muscarinic receptor subtypes stably expressed in A9 L cells. Proc Natl Acad Sci USA 1988; 85: 8698-702.
30. Van Koppen CJ, Kaiser B. Regulation of muscarinic acetylcholine receptor signalling. Pharmacol Ther 2003; 98: 197-220.
31. Cui QL, Fogle E, Almazan G. Muscarinic acetylcholine receptors mediate survival through Src-like tyrosine kinase and PI3K/Akt pathways. Neurochem Int 2006; 48: 383-93.
32. Kruse AC, Kobilka BK, Gautam D, Secton PM, Christopoulos A, Wess J. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev 2014; 13: 549-60.
33. Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007; 6: 721-33.
34. Stockton JM, Birdsall NJM, Burgen AS, Hulme EC. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 44: 102-10.
35. Ellis J, Seidenberg M, Brann MR. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1993; 42: 199-205.
36. Birdsall NJM, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sci 1997; 60: 1047-52.
37. Holzgrabe U, De Amici M, Mohr K. Allosteric modulators and selective agonists of muscarinic receptors. J Mol Neurosci 2006; 30(1-2): 165-68.
38. Bolognesi ML, Minarini A, Budriesi R, Cacciaguerra S, Chiarini A, Spampinato S, et al. Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. J Med Chem 1998; 41: 4150-60.
39. Jerulinsky D, Cervenansky C, Pena C, Raskovsky S, Dajas F. Two polypeptides from Dendroaspis angusticeps venom selectivity inhibit the binding of central muscarinic cholinergic receptor ligands. Neurochem Int 1992; 20: 237-46.
40. Max SI, Liang JS, Potter LT. Purification and properties of m1-toxin, a specific antagonist of m1 muscarinic receptors. J Neurosci 1993; 13: 4293-300.
41. Shannon HE, Sheardown MJ, Bymaster FP, Calligaro DO, Delapp NW, Gidda J, et al. Pharmacology of butylthio [2. 2. 2] (LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-94.
42. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 2012; 55: 1445-64.
43. Conn, J. P., Lindsley, C. W., Hopkins, C. R., Chauder, B. A., Gogliotti, R. D., Wood, M. R. Substituted 1H-pyrrolo[3, 2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4. WO2012154731A1 (2012).
44. Felder CC, Bymaster FP, Ward J, Delapp N. Therapeutic opportunities for muscarinic receptors in central nervous system. J Med Chem 2000; 43: 4333-53.
45. Hedge SS, Mammen M, Jasper JR. Anti-muscarinic for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Inv Drugs 2004; 5: 40-49.
46. Eglen RM. Muscarinic receptor subtypes in neuronal and nonneuronal cholinergic function. Autonomic Autocoid Pharmacol 2005; 26: 219-33.
47. Postlind H, Danielson A, Lindgren A, Andersson SH. Tolterodine: a new muscarinic receptor antagonist, is metabolized by cytochrome P4502D6 and 3A4 in human liver microsomes. Drug Metab Dispos 1998; 26: 289-93.
48. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive blabber syndrome. Expert Opin Pharmacother 2008; 9: 1787-96.
49. Arth, C., Komenda, M., Bicane, F., Paulus, K., Irngartinger, M., Lindner H. US 20080318421 (2008).
50. Oki T, Maruyama S, Takagi Y, Yamamura HI, Yamada S. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice. Europ J Pharmacol 2006; 529: 157-63.
51. Racke K, Jurgens UR, Matthiesen S. Control by cholinergic mechanisms. Eur J Pharmacol 2006; 533: 57-68.
52. Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther 2004; 17: 181-98.
53. Dale PR, Cernecka H, Schmidt M, Dowling MR, Charlton SJ, Pieper MO, et al. The pharmacological rationale for combining muscarinic receptor antagonists and α-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Op Pharmacol 2014; 16: 31-42.
54. Keam SJ, Keating GM. Tiotropium bromide: a review of its use as maintenance therapy in patients with COPD. Treat Resp Med 2004; 3: 247-68.
55. Fox RI. Sjogren's syndrome: evolving therapies. Expert Opin Invest Drugs 2003; 12: 247-54.
56. Matsunami, H., Li, Y. Compositions and methods for enhancing odorant receptor activity. US2013004983A1 (2013).
57. Eglen RM, Choppin A, Dillon MP, Hegde S. Muscarinic receptor ligands and their therapeutic potential. Curr Op Chem Biol 1999; 3: 426-32.
58. Takeuchi, M., Naito, R., Hayakawa, M., Okamoto, Y., Yonetoku, Y., Ikeda, K., Isomura, Y. Quinuclidine derivatives and medicinal composition thereof. US20006017927 (2000).
59. Meese, C., Sparf, B. Novel derivatives of 3, 3-diphenylpropylamines. US2004186061 (2004).
60. Cross, P., Mackenzie, A. R. Pyrrolidine derivatives. US5096890 (1992).
61. Dolan, T. F., Humphrey, M. J., Nichols, D. J. System, computer program product and method of narrowing an enterprise Java bean (EJB) object reference to a home implementation class name. US2006106864 (2000).
62. Karl, Z., Werner, S., Rolf, B., Helmut, W. N-hydrocarbylsubstituted noratropinium, haloalkylates and o-acyl derivatives thereof. US3505337 (1970).
63. Zeile, K., Banholzer, R., Walther, G., Schulz, W., Wick, H. Nsubstitution products of norscopolamine and quaternary salts thereof. US3472861 (1969).
64. Box, P. C., Coe, D. M., Looker, B. E., Procopiou, P. A. Phenethanolamine derivatives. US007271197B2 (2007).
65. Box, P. C., Coe, D. M., Looker, B. E., Procopiou, P. A. Phenethanolamine derivatives. US2005256201 (2005).
66. Banholzer, R., Bauer, R., Reichl, R. Esters of thienyl carboxylic acids and amino alcohols and their quaternization products. US5610163 (1997).
67. Joensson, N. A., Sparf, B. A., Mikiver, L., Moses, P., Nilvebrant, L., Glas, G. 3, 3-diphenylpropylamines and pharmaceutical compositions thereof. US5382600 (1995).
68. Laine, D., Palovich, M. R., McCleland, B. W., Neipp, C. E., Thomas, S. M. Muscarinic acetylcholine receptor antagonists. US8183257 (2012).
69. Laine, D., Palovich, M. R., McCleland, B. W., Neipp, C. E., Thomas, S. M. Muscarinic acetylcholine receptor antagonists. EP1740177B1 (2012).
70. Laine, D., Palovich, M. R., McCleland, B. W., Neipp, C. E., Thomas, S. M. Muscarinic acetylcholine receptor antagonists. US20120157491A1 (2012).
71. Meese, C., Sparf, B. Novel derivatives of 3, 3-diphenylpropylamines. US7855230B2 (2009).
72. Laine, D., Palovich, M. R., McCleland, B. W., Neipp, C. E., Thomas, S. M. Muscarinic acetylcholine receptor antagonists. US8309572 (2012).
73. Pfister, J. R., Rescourio, G., Venkatraman, M. S., Zhang, X. 7-azoniabicyclo[2. 2. 1]heptane derivatives, methods of production, and pharmaceutical uses thereof. US20120029044A1 (2012).
74. Leonardi, A., Motta, G., Riva, C., Testa, R. Thienopyranecarboxamide derivatives. US006486163B1 (2001).
75. Kim, Y., Kang, S. B., Keum, G., Jang, M. S., Kong, J. Y., Jeong, D. Y. Tetrahydropyridine derivatives acting on muscarinic acetylcholine receptors. US20030119880A1 (2002).
76. Bymaster, F. P., Horstmann, M., Shannon, H. E., Shipley, L. A., Valia, K. H. Transdermal formulation of xanomeline. US5980933 (1999).
77. Fisher, A., Karton, I., Heldman, E., Levy, A., Grunfeld, Y. Derivatives of quinuclidine. US4855290 (1989).
78. Hayashi, K., Tokumoto, S., Yoshizawa, H., Isogai, T., Kimura, M., Sawaki, M., Ando, T., Katsuyama, I., Ariyoshi, H., Nakamura, T. Method for producing 2-methylspiro(1, 3-oxathiolane-5, 3')quinuclidine. US5571918 (1996).
79. Grewal, G., Toy-Palmer, A., Cai, X., Lathman, G. M. Muscarinic agonists and antagonists. US006323194B1 (2000).
80. Shannon HE, Sheardown JM, Bymaster FP, Calligaro DO, Delapp NW, Gidda J, et al. Pharmacology of Butylthio [2. 2. 2](LY297802/NNC11-1053): a novel analgesic with mixed muscarinic receptor agonist and antagonist activity. J Pharmacol Exp Ther 1997; 281: 884-94.
81. Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for treatment of CNS disorders. Neurobiol Dis 2014; 61: 55-71.
82. Hasselmann H. Scopolamine and depression: a role for muscarinic antagonism? CNS Neurol Disord Drug Targets 2014; 13: 673-83.
83. Dreverts WC, Zarate CA, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psich 2013; 73: 1156-63.
84. Francis P, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzeihmer's disease: a review of progress. J Neurol Neurosurg Pychiatry 1999; 66: 137-14.
85. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer's disease. Proc Natl Acad Sci USA 1996; 93: 13541-46.
86. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioural symptoms in a Alzheimer disease. Arch Neurol 1997; 54: 465-73.
87. Melancon BJ, Gogliotti RD, Tarr JC, Saleh SA, Chauder BA, Lebois EP, et al. Continued optimization of the MLPCN probe ML071 into higly potent agonist of the M1 muscarinic acetylcholine receptor. Bioorg Med Chem Lett 2012; 22: 3467-72.
88. Klose, K. T. J., Tran, N. T. K., Matthias, T., Finnin, B. C., Reed, B. L. Transdermal delivery of antiparkinson agents. US6929801 (2005).
89. Newman, A. H., Zou, M. F., Katz, J. L. Benztropine compounds and uses thereof. US20080226559 (2008).
90. Sur C, Kinney GG. Selective targeting of Muscarinic receptors: novel therapeutic approaches for psychotic disorders. Curr Neuropharmacol 2005; 3: 63-71.
91. Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, et al. A regenerative approach to the treatment of multiple sclerosis. Nature 2013; 502: 327-35.
92. Reale M, De Angelis F, Di Nicola M, Capello E, Di Ioia M, De Luca G, et al. Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci 2012, 13, 12656-64.
93. Sailer M, Oppitz M, Drews U. Induction of cellular contractions in the human melanoma cell line SK-mel 28 after muscarinic cholinergic stimulation. Anat Embryol 2000; 201: 27-37.
94. Oppitz M, Möbus V, Brock S, Drews U. Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecologic Oncol 2002; 85: 159-64.
95. Rayford W, Noble MJ, Austenfeld MA, Weigel J, Mebust WK, Shah GV. Muscarinic cholinergic receptors promote growth of human prostate cancer cells. The prostate 1997; 30: 160-66.
96. Frucht H, Jensen RT, Dexter D, Yang Wl, Xiao Y. Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor. Clinical Cancer Res 1999; 5: 2532-39.
97. Song P, Sekhon HS, Lu A, Arredondo J, Sauer D, Gravett C, et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Res 2007; 67: 3936-44.
98. Guizzetti M, Costa P, Peters J, Costa LG. Acetylcholine as a mitogen: muscarinic receptor-mediated proliferation of rat astrocytes and human astrocytoma cells. Eur J Pharmacol 1996; 297: 265-73.
99. Boss A, Oppitz M, Drews U. Muscarinic cholinergic receptors in the human melanoma cell line SK-MEL28: modulation of chemotaxis. Exp Dermatol 2005; 30: 557-64.
100. Rimmaudo LE, De la Torre E, Sacerdote de Lusting E, Sales ME. Muscarinic receptors are involved in LMM3 tumor cells proliferation and angiogenesis. Biochem Bioph Res Comm 2005; 334: 1359-64.
101. Jimenez E, Montiel M. Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-86.
102. Ferretti M, Fabbiano C, Di Bari M, Ponti D, Calogero A, Tata AM. M2 muscarinic receptor inhibits cell proliferation in human glioblastoma cell lines. Life Sci 2012; 91: 1134-37.
103. Ferretti M, Fabbiano C, Ricordy R, Conte C, Castigli E, Sciaccaluga M, et al. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells. J Cell Mol Med 2013; 17(4): 552-66.
104. Song P, Sekhon HS, Jia Y, Keller JA, Blusztajn JK, Mark GP, et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. Cancer Res 2003; 63: 214-21.
105. Jimenez E, Montiel M. Activation of MAP kinase by Muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells. J Cell Physiol 2005; 204: 678-86.
106. Guizzetti M, Wei M, Costa LG. The role of protein kinase C+ and isozymes in DNA synthesis induced by muscarinic receptors in a glial cell line. Eur J Pharmacol 1998; 359: 223-33.
107. Bordey A, Sontheimer H, Thouslard J. Muscarinic activation of BK channels induces membrane oscillations in glioma cells and leads to inhibition of cell migration. J Membrane Biol 2000; 176: 31-40.
108. Pacini L, De Falco E, Di Bari M, Coccia A, Siciliano C, Ponti D, et al. M2 muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells. Cancer Biol Ther 2014; 15: doi: 10. 4161/15384047. 2014. 955740.
109. Golz, S., Brueggemeier, U., Summer, H. Diagnostics and therapeutics for diseases associated with muscarinic acetylcholine receptor M2 (M2). WO04057344A1 (2004).
110. Arora, R., Kadish, A., Gilchrist, A. Information recording apparatus. US8103151 (2012).
111. Skerjanec A. The clinical pharmacokinetics of darifenacin. Clin Pharmakinet 2006; 45: 325-50.
112. Song P, Spindel ER. Basic and clinic aspect of non neuronal acetylcholine: expression of non neuronal acetylcholine in lung cancer provides a new target for cancer therapy. J Pharmacol Sci 2008; 106: 180-85.
113. Nakae K, Nishimura Y, Ohba S, Akamatsu Y. Migrastatin acts as a muscarinic acetylcholine receptor antagonist. J Antibiot 2006; 59: 685-92.
114. Bernardini N, Levey AI, Augusti TG. Rat dorsal root ganglia express m1-m4 muscarinic receptor proteins. J Pheripher Nervous Sys 1999; 4: 222-32.
115. Tata AM, Vilaró MT, Mengod G. Muscarinic receptor subtypes expression in rat and chick dorsal root ganglia. Mol Brain Res 2000; 82: 1-10.
116. Iwamoto ET, Marion L. Characterization of the antinociception produced by intrathecally administered muscarinic agonistsin rats. J Pharmacol Exp Ther 1993; 266: 329-38.
117. Widman M, Tucker S, Brase DA, Dewey WL. Cholinergic agents: antinociception without morphine type dependence in rats. Life Sci 1985; 36: 2007-15.
118. Wess J, Duttaroy A, Gomeza J, Zhang W, Yamada M, Felder CC, et al. Muscarinic receptor subtypes mediating central and periph eral antinociception studied with muscarinic receptor knockout mice: a review. Life Sci 2003; 72: 2047-54.
119. Honda K, Harada A, Takano Y, Kamira H. Involvement of M3 muscarinic receptors of the spinal cord in formalin-induced nociception in mice. Brain Res 2000; 859: 38-44.
120. Bernardini N, Sauer S, Haberberger R, Fisher MJM, Reeh PW. Excitatory nicotinic and desensitizing muscarinic (M2) effects on C-nociceptors in isolated rat skin. J Neurosci 2001; 21: 3295-302.
121. Bernardini N, Roza C, Sauer S, Gomeza J, Wess J, Reeh W. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci 2002; 22: 1-5.
122. Dussor GO, Helesic G, Hargreaves KM, Flores CM. Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron. Pain 2004; 107: 22-32.
123. De Angelis F, Marinelli S, Fioretti B, Catacuzzeno L, Franciolini F, Pavone F, et al. M2 receptors exert analgesic action on DRG sensory neurons by negatively modulating VR1 activity. J Cell Physiol 2014; 229: 783-90.
124. Ellis JL, Harman D, Gonzalez J, Spera ML, Liu R, Shen TY, et al. Development of muscarinic analgesic derived from epibatidine: role of the M4 receptor subtype. J Pharmacol Exper Ther 1999; 288: 11431150.
125. Rubio, E. A., Hilliard, D. W. Thienopyridines as allosteric potentiators of the M4 muscarinic receptor. US8071776 (2011).
126. Gregory KJ, Sexton PM, Christopoulos A. Allosteric modulation of muscarinic acetylcholine receptors. Curr Neuropharmacol 2007; 5(3): 157-67.
127. De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, Mohr K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 2010; 30(3): 463-549.
128. Valant C, Lane JR, Sexton PM, Christopoulos A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 2012; 52: 153-78.
129. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S, et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol 2003; 64(1): 21-31.
130. Prilla S, Schrobang J, Ellis J, Höltje HD, Mohr K. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2 422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol 2006; 70(1): 181-93.
131. Birdsall NJ, Lazareno S. Allosterism at muscarinic receptors: ligands and mechanisms. Mini Rev Med Chem 2005; 5(6): 523-43.
132. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007; 320(1): 1-13.
133. Sanchez-Fernandez G, Cabezudo S, Garcia-Hoz C, Tobin AB, Mayor F Jr, Ibas C. Erk5 activation by Gq-coupled muscarinic receptors is independent of receptor internalization and α-arrestin recruitment. Plos One 2013; 8: e84174.
134. Leach K, Loiacono RE, Felder CC, McKinzie DL, Mogg A, Shaw DB, et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacol 2010; 35(4): 855-69.
135. Stewart GD, Sexton PM, Christopoulos A. Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. Mol Pharmacol 2010; 78(2): 205-14.
136. Portoghese PS, Nagase H, Lipkowski AW, Larson DL, Takemori AE. Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem 1988; 31(4): 836-41.
137. Portoghese PS. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol Sci 1989; 10(6): 230-5.
138. Valant C, Sexton PM, Christopoulos A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv 2009; 9(3): 125-35.
139. Mohr K, Tränkle C, Kostenis E, Barocelli E, De Amici M, Holzgrabe U. Rational design of dualsteric GPCR ligands: quests and promise. Br J Pharmacol 2010; 159(5): 997-1008.
140. Kruse AC, Janxin H, Kobilka BK, Wess J. Muscarinic acetylcholine receptors X-ray structures: potential implications for drug development. Curr Op Pharmacol 2014; 16: 24-30.
141. Disingrini T, Muth M, Dallanoce C, Barocelli E, Bertoni S, Kellershohn K, et al. Design, synthesis, and action of oxotremorinerelated hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J Med Chem 2006; 49(1): 366-72.
142. Antony J, Kellershohn K, Mohr-Andrä M, Kebig A, Prilla S, Muth M, et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J 2009; 23(2): 442-50.
143. Bock A, Merten N, Schrage R, Dallanoce C, Bätz J, Klöckner J, et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. Nat Commun 2012; 3: 1044.
144. Matera C, Flammini L, Quadri M, Vivo V, Ballabeni V, Holzgrabe U, et al. Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity. Eur J Med Chem 2014; 75C: 222-32.
145. Mammen, M., Wilson, R., Dunham, S., Hughes, A., Husfeld, C., Ji, Y.-H., Li, L., Mischki, T., Stergiades, I., Oare, D. Substituted 4-Amino-1-Benzylpiperidine compounds. WO2005007645A1 (2005).
146. Steinfeld T, Mammen M, Smith JA, Wilson RD, Jasper JR. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol 2007; 72(2): 291-302.
147. Davie BJ, Christopoulos A, Scammells PJ. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. ACS Chem Neurosci 2013; 4(7): 1026-48.
148. Lindsley, C. W., Conn, P. J., Wood, M. R., Gogliotti, R. D., Niswender, C. M., Melancon, B. J., Lebois, E. P. Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3. 2. 1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same. WO2011087812A1 (2011), also published as US20110172227A1 (2011).
149. Boulos, J. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof. WO2014014698A2 (2014), also published as US20140018366A1 (2014).
150. Steidl S, Miller AD, Blaha CD, Yeomans JS. M5 muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice. PLoS One 2011; 6(11): e27538.
151. Mammen, M., Yu-Hua, J., Dunham, S., Li, L. Diphenylmethyl compounds useful as muscarinic receptor antagonists. US007151115B2 (2006).
152. Drutu, I., Hurley, D. J., Bandarage, U. P., Bergeron, D. J., Charifson, P. S., Davies, R. J., Blanco, G. G., Makings, L. R., Nakatani, A., Raffai, G. Modulators of muscarinic receptors. US20060270653A1 (2007).